Evaluation of different radiological interventional treatments of Budd–Chiari syndrome  by Al-warraky, M. et al.
The Egyptian Journal of Radiology and Nuclear Medicine (2015) 46, 1011–1020Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comORIGINAL ARTICLEEvaluation of diﬀerent radiological interventional
treatments of Budd–Chiari syndrome* Corresponding author.
Peer review under responsibility of Egyptian Society of Radiology and
Nuclear Medicine.
http://dx.doi.org/10.1016/j.ejrnm.2015.07.003
0378-603X  2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).M. Al-warraky a,*, E. Tharwa b, M. Kohla b, M.A. Aljaky b, A. Aziz ca Radiology Department, National Liver Institute, Egypt
b Hepatology Department, National Liver Institute, Egypt
c Surgery Department, National Liver Institute, EgyptReceived 14 October 2014; accepted 6 July 2015
Available online 24 August 2015KEYWORDS
Budd–Chiari syndrome;
Dilatation;
Transluminal angioplasty;
Shunt;
TIPSAbstract Aim: To evaluate the efﬁcacy of various interventional techniques in treatment of
Budd–Chiari syndrome (BCS).
Patients methods: 103 patients with BCS were included in the study. There were 9/103 (8.7%)
patients with obstruction of inferior vena cava (IVC) (type I), 17/103 (16.6%) patients with hepatic
vein obstruction (type II), 71/103 (68.9%) patients with veno-occlusive diseases (type III) and 6/103
(5.8%) patients with veno-occlusive disease combined with caval thrombosis (type IV). Recanaliza-
tion techniques of hepatic veins and IVC, and TIPS were used.
Results: Of all the subjects, 101 successfully underwent their procedures, with a technical success
rate of 98.06%; only 2 failed to do TIPS. After treatments, 2 patients died after operation because
of severe intra-abdominal hemorrhage. One hundred and one patients were followed up for
1–94 months. The mean follow-up of a BCS patient treated with PTA was 52.1 months, with an
overall primary patent rate of 69.2% (18/26). The mean follow-up of BCS treated with TIPS was
33.5 months, with an overall primary patent rate of 72.7% (56/77). Eight patients died 7–64 months
after the interventions.
Conclusions: Recanalization of IVC/hepatic vein and TIPS can be regarded as safe and effective
interventional invasive methods in the treatment of BCS.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Budd–Chiari syndrome (BCS) represents a series of patholog-
ical changes resulting from occlusive lesions in the hepatic
veins and/or the inferior vena cava (IVC). The clinicalmanifestations of BCS include hepatomegaly, abdominal
pains, ascites, and edema of the low limbs. It is an uncommon
worldwide disease, but its incidence in China and other Asian
countries is relatively high (1). In Western countries, primary
myeloproliferative syndromes, hypercoagulable states and
steroidal contraceptives were responsible for most cases. In
Asian countries, pregnancy, infections and an inferior vena
cava were the dominating causes (2). The prognosis for BCS
is poor, and is usually difﬁcult to cure. In recent years,
Table 1 Classiﬁcation of 103 patients with BSC based on ultrasound and angiography.
Types N (%)
Type I: Membranous obstruction of the IVC W/WO thrombosis 9/103 (8.7)
Type II: Solitary hepatic vein obstruction (web/thrombosis) 17/103 (16.6)
Type III: Rudimentary (diﬀuse thrombosis) of hepatic veins 71/103 (68.9)
Type IV: Rudimentary (diﬀuse thrombosis) of hepatic veins with caval thrombosis 6/103 (5.8)
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as a safe and effective technique (3). However, there are still
many urgent tasks not only in the selection of indicators, but
also in the improvement of long-term results. Percutaneous
interventional radiology procedures have been recently
proposed as an alternative to surgical shunting and liver trans-
plantation (4,5). These interventional techniques depend on
the type of BCS. In 2003, a classiﬁcation scheme of BCS devel-
oped and proposed type I as caval occlusion, type II as short
segment (<4 cm) isolated hepatic vein occlusion, type III as
rudimentary/totally thrombotic hepatic veins and type IV that
involves combined thrombosis of the hepatic veins and caval
thrombosis (6).
The purpose of our study was to evaluate the feasibility and
efﬁcacy of those different interventions for the treatment of
patients with BCS.2. Subjects and methods
This retrospective cohort study was conducted at the
National Liver Institute, Menouﬁya University from Octo-
ber 2006 to April 2013. It included 103 patients having
Budd–Chiari syndrome who were selected and submitted
for the treatment with interventional procedures. All
patients had informed consents before interventions. Gener-
ally, there were 73 females and 30 males. Their ages ranged
from 14 to 44 years, with a mean of 29.5 years. The
duration of symptoms ranged from 1 to 10 years. Clinical
symptoms observed included abdominal pain and distention,
hepatomegaly, splenomegaly, ascites and varicose veins in
the abdomen and legs.
On the basis of angiography and ultrasonography, 103
patients were classiﬁed into 4 types of BCS (Table 1): type I
solitary obstruction of the IVC by membrane/thrombosis
(9/103; 8.7%), type II solitary short segment/membranous
hepatic vein obstruction (17/103; 16.6%), type III rudimen-
tary/diffuse thrombotic obstruction of the hepatic veins
(veno-occlusive disease) (71/103; 68.9%) and type IV
combined thrombosis of the hepatic veins and retro-hepatic
cava (6/103; 5.8%). For those of caval obstruction, the length
of obstructed IVC ranged from 1 to 2 cm and the width ranged
from 16 to 22 cm. Obstructive hepatic vein ranged from 1 to
4 cm and 0.8 to 1 cm wide. All operations were performed
under the guidance of standard angiography (Fluoroscopic
X-ray DIGITAL unit: inﬁnix, Toshiba, Japan) with ultra-
sound guidance (Toshiba-xario with 5 MHZ convex trans-
ducer and Toshiba nemio XG with 3.75 MHZ convex
transducer).2.1. Methodology
2.1.1. Treatment of type I Budd–Chiari by caval recanalization
(9 patients)
Caval recanalization by dilatation with or without shunting is
considered the best option for such patients. In all patients, we
used primarily the femoral vein to obtain inferior vena cavog-
raphy to evaluate for the site and degree of occlusion. In cases
of incomplete occlusions, the contrast passed to opacify the
heart. In such cases, we passed the guide wire through the
stenosis followed by the large-diameter balloon (20–24 mm)
and dilatation was obtained. If occlusion was complete,
RUPS-100 (Rosch-Uchida Puncture Set) device or J-type
Brockenbrough needle (Cook, Chicago, USA) was passed
from the jugular vein. While the pigtail catheter was in cava
(from femoral vein), lateral view was obtained to have
alignment straight positioning. Once optimal alignment was
obtained in anterior and lateral projections, the Rups100 or
Brockenbrough needle was pushed slowly to penetrate the
occlusion segment till it reaches the other side. Blood was aspi-
rated to conﬁrm luminal position and then wire was advanced
while the needle is removed. The large-diameter balloon was
then advanced to dilate the segment (Figs. 1 and 2).
2.1.2. Treatment of type 2 by hepatic vein recanalization (17
patients)
For recanalization of one of the hepatic veins, transjugular or
trans-hepatic approach was used. In some cases, combined
approaches were used. As a rule, we used the transjugular
approach at ﬁrst, where a long sheath was inserted. Catheter
manipulation was done to go through the narrowed ostium.
After passing, 10–12 mm balloon was inserted and the ostium
was dilated. In case of failure to pass through the stenosis
(total occlusion), the RUPS-100 needle was inserted at the
osteal occlusion and pushed to get the balloon after. If tran-
sjugular approach failed, trans-hepatic approach was used.
Under US guidance, the proper hepatic vein was punctured
and manipulation was performed to pass the occluded segment
to get the dilatation (Figs. 3–5).
2.1.2.1. Shunting of cava and hepatic vein. We used shunts for
patients with type 1 and type 2 in case of immediate recoil at
the time of operation, in case of failure to dilate or in late cases
with recurrent stenosis/occlusion.
For caval shunting, balloon-mounted shunts of diameter 2–
4 mm larger than the diameter of cava and longer by 2–3 cm
from that of the occlusion length. The shunt was introduced
through the suitable sheath (12 Fr). The shunt set was advanced
Fig. 1 Dilatation of totally occluded membraneous web of the IVC. (A) Vena cavography through femoral approach showed a 2 cm
long caval obstructing web with no ﬂow to the heart. The occlusion could be passed and a large balloon dilatation was done (B). Serial
dilatations of the obstructing segments by kissing balloons; from the jugular and femoral approaches (C and D). Post-dilation of the web
with free ﬂow to the heart (E).
Fig. 2 Treatment of caval obstructing web/old thrombosis. (A) A 2 cm long caval obstructing web with no ﬂow to the heart. Sheath
from the jugular vein contains the TIPS needle meeting the pig tail from femoral approach. (B) Kissing balloons; from the jugular and
femoral approaches. (C) Post-dilation of the web with free ﬂow to the heart.
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shunt.
For hepatic vein shunting, self-expandable metallic shunts
such as Wallshunt (Schneider shunt Inc., Minneapolis, Min-
nesota, USA) of 10–12 mm diameter was used. The shunt
was advanced and centered in position. The outer sheath was
then pulled back to allow shunt expansion.2.1.3. Treatment of type 3 and type 4 by porto-systemic shunting
(77 patients)
Porto-systemic shunting was utilized for groups 3 and 4 BCS
with ascites or hemorrhage of the upper digestive system when
no chance to re-canalize the cava or hepatic veins. The diagno-
sis of diffuse obstruction of the hepatic vein mainly depended
on ultrasonography or CT. Because of the diffuse obstruction
Fig. 3 Middle Hepatic vein balloon dilatation for isolated hepatic vein obstruction. (A) Middle hepatic venography via percutaneous
approach showed total occlusion of the hepatic vein at the junction with the cava with numerous venous collateral. (B) Angiography after
dilation shows patent middle hepatic vein with free ﬂow to the heart and absent collateral channels.
Fig. 4 Percutaneous balloon dilatation of the left hepatic vein for isolated hepatic vein obstruction. (A) Hepatic venography via
percutaneous approach showed subtotal occlusion of the hepatic vein at the junction with the cava. (B) Angiography after dilation shows
patent oriﬁce of the hepatic vein with free ﬂow to the heart.
Fig. 5 Middle Hepatic vein dilatation and shunting for isolated hepatic vein obstruction. (A) Hepatic venography via percutaneous
approach showed total occlusion of the hepatic vein at the junction with the cava with numerous venous collateral. A snare passed from
jugular approach to catch the wire to pass the suitable balloon. (B and C) Dilatation of the hepatic vein ostium by a balloon passing from
the jugular vein. Waist is seen in (B) and lost in (C) signifying efﬁcient dilatation. Angiography after dilation and shunting shows patent
vascular channel with free ﬂow to the heart and absent collateral channels (D).
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Fig. 6 TIPS in Budd–Chiari patient: The TIPS needle is advanced through the inferior cavogram (A). The needle was then advanced
through the caval wall inside the liver tissue to reach the right PV (B). Sheath replaced the needle in (C). Two Wallshunts were then
deployed between the PV and cava and portography (D) shows good intra-shunt ﬂow.
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hepatic vein; therefore, the portal vein was punctured directly
from the IVC to establish a portal-IVC shunt (Figs. 6 and 7).
Two types of shunts were used. The ﬁrst was the uncovered
type that was Wallshunt while the second was covered type
that was Viatorr shunt (GORE Company USA). The
following two approaches were used to insert the porto-caval
shunt:
a. Trans-jugular intra-hepatic portosystemic shunt (TIPS)
(55 patients)
Right internal jugular access was used. TIPS cannula
(Transjugular Liver Access Set; Cook, Bloomington, IN,
USA) was used, but its curvature was modiﬁed whenever
required. The image intensiﬁer was kept 45 degrees oblique
toward the left side. Trans-abdominal US in oblique sagittal
plane provided excellent guidance for estimating the length
and course of the shunt. The ﬂuoroscope and US were perpen-
dicular to each other. A point just below the expected HV con-
ﬂuence level was selected to initiate the tract. The cannula and
needle were directed toward the right branch of portal vein,
close to the portal conﬂuence.
The punctures were performed using a Rosch Uchida
needle (Cook). Care was taken not to traverse beyond the por-
tal vein. Additional manipulations were sometimes required to
direct the glide wire toward the main portal vein instead of itsright branch. After accessing the portal vein, pressure gradient
was measured. Balloon angioplasty was performed prior to
placement of the shunt. An extra length of the shunt was kept
in the IVC, so that its end was directed upwards rather than
against the opposite wall of the IVC. Check venogram and
pressure gradient measurements were performed.
b. Direct intrahepatic porto-systemic shunts (DIPS) (22
patients)
Punctures were made into the right portal vein to the IVC
using a freehand technique. In these patients, an intercostal
approach was necessary so that ascetic ﬂuid could be drained
before the procedure to facilitate percutaneous puncture.
Right portal venous puncture to the right anterior portal vein
was performed close to the right portal venous trunk. When
portal venous puncture was accomplished, contrast medium
was injected for visualization of the location of the needle
tip, and the needle was further advanced without a change in
the insertion angle to puncture the IVC. The position of the
needle was again conﬁrmed with injection of contrast medium.
A stiff 0.035-inch guidewire was advanced through the Chiba
needle to the IVC. Guidewire manipulation was kept to a min-
imum to reduce the risk of shearing the coating of glidewires
introduced through a beveled needle. At this stage, an
8-French sheath was placed into the IVC through the right
internal jugular vein. A Dormia basket was introduced
Fig. 7 TIPS in Budd–Chiari patient of group (4): The inferior cavogram (A) showed IVC and TIPS needle. Trans-caval puncture was
performed to reach the RPV (B). The catheter was advanced to reach main portal to get portography (C) before shunting. Two Viatorr
shunts were implanted and portography (D) shows good intra-shunt ﬂow to the heart.
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to achieve through-and-through access. The Chiba needle was
pulled back 2 cm to dilate the intrahepatic track with an 8-mm
ultrathin balloon advanced through the 8-French sheath.
When the balloon catheter was advanced to the intrahepatic
track, sonography was performed to determine that the bal-
loon was not advanced beyond the entrance to the portal vein.
An 8-French sheath was advanced to the entrance of the portal
vein. A 5-French cobra catheter and a 0.035-inch glidewire
were introduced through the sheath, and both catheter and gli-
dewire were manipulated into the main portal vein and the
superior mesenteric vein. Heparin (5000 IU) was administered
IV. The through-and-through glidewire was kept in place for
safety. After portography and pressure measurement, a
0.035-inch Amplatz guidewire was advanced to the portal sys-
tem. The hepatic track was again dilated with an 8-mm balloon
the through-and-through.2.2. Treatment after operation
Patients were systemically treated with low molecular weight
heparin with oral anticoagulants for a period of 5–7 days. This
is to adjust the INR between 2 and 3. Some patients were given
aspirin and dipyridamole orally for 6 months.2.3. Follow-up evaluation
Symptoms including ascites and dilated parietal abdominal
veins were observed (Fig. 8). Follow-up ultrasonographies
were performed every 3–6 months and follow-up venographies
were performed once or twice over a year according to
requirements.
3. Results
One hundred and three patients with Budd–Chiari were sub-
jected to the interventional treatments, either by recanalization
or by porto-systemic shunting. Treatment succeeded techni-
cally in 101/103 patients giving an overall success rate of
98.06%. Among the 103 patients, there were 26 patients for
recanalization in either cava (9 patients) or the hepatic veins
(17 patients). The rest of the patients (77 patients) were treated
by porto-systemic shunts.
Generally, for recanalization techniques, 9 patients with
caval lesions had complete occlusion (4 patients) or incomplete
occlusion vein lesions (5 patients). All of them had membra-
nous obstruction with different thicknesses ranging from 0.5
to 2 cm. The lesions of the hepatic venous obstruction ranged
from 1 to 4 cm.
Before Aer Before Aer
BA DC
Fig. 8 Clinically this young boy (A and B) complained of dilated venous channels on the lateral abdominal wall (A). After dilatation of
his obstructed cava, most of the veins disappeared. Residual small veins are still seen (B). The other 2 pictures for another 21 year old boy
having ascites and dilated abdominal veins (C). These disappeared after doing TIPS (D).
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ever, shunting was done for the ﬁrst time in 2/26 patients
(7.6%) and both patients had hepatic vein lesion. None of
the caval lesion was shunted primarily.
For portosystemic shunting, 77 patients out of 103 of the
Budd–Chiari were subjected to such operation. Shunt insertion
succeeded technically from the ﬁrst trial in 75/77 patients giv-
ing overall success rate of 97.4%. Shunt insertion failed in 2
patients because of inability to reach the portal vein inside
the liver. The shunt was inserted using the TIPS approach in
55 patients while DIPS approach in 22 patients. The uncovered
Wallshunt was used in 59 patients while the covered Viatorr
shunt was used in 16 patients.
In our series, patients with BCS achieved satisfactory
results after the therapy of much improved venous drainage.
Venography showed that the diameter of recanalized veins
reached more than 80% of the normal diameter. Collateral cir-
culation disappeared. The average venous pressure in the distal
area of the hepatic vein was markedly lower. After PTA or
shunt implantation, pressure in the hepatic vein declined from
43.8 ± 12.9 to 16.4 ± 2.3 cm H2O, while pressure in IVC
increased from 13.4 ± 3.6 to 28.9 ± 9.8 cm H2O.
3.1. Re-occlusion after interventions
The 26 patients (hepatic vein 17 and IVC 9) who had under-
gone recanalizations, were followed up for an average period
of 52.1 months (1–94 months). The primary patency rate for
PTA was 41.6% as 10/24 patients had re-stenosis (9 in hepatic
veins and 1 in the IVC. Ten patients had undergone shunt
implantation including 9 patients with hepatic vein re-
stenosis and 1 patient with re-stenosed cava. The average
follow-up period for them was 33.5 months (3–62 months).The primary-assisted patency rate was 100% with these 10
patients having shunting after re-stenosis. The re-stenosis rate
for hepatic vein occlusion treated with PTA was (9/15) 60%
while it was 0% when treated with shunt implantation. The
rate of re-stenosis for the IVC treated with PTA was 11.1%.
The rate of re-stenosis in hepatic veins (60%) having under-
gone PTA was higher than that of the IVC with the same treat-
ment (11.1%), while the same rate for hepatic veins (0%)
having undergone shunt as that of the IVC with the same treat-
ment (0%). No patient out of the 11 patients of the hepatic
vein shunting got restenosed. Shunt thrombosis (early compli-
cations) occurred in 3/11 (27.2%) patients and all of them were
treated by thrombolysis and thrombus suction.
Regarding shunt patency of different approaches for shunt
insertion, 14/22 patients with DIPS approach got occluded
ﬁrst year of follow-up with primary patency rate of 36.3%.
For patients with TIPS, 7/53 patients got occluded ﬁrst year
of follow-up with primary patency rate of 86.7%. Those
patients were treated with shunt dilatation.
The results of the porto-systemic shunt patency with differ-
ent types of shunts are shown in Table 2.
3.2. Clinical end points
Of the 101 patients who completed the treatment, in 91
patients (90.1%), the symptoms of ascites completely resolved.
In 9 patients (8.9%) symptoms of ascites partially (incom-
pletely) resolved. So, the overall response rate was 99%. Only
one patient did not show any improvement. The clinical data
of Budd–Chiari before and 2 months after treatment are
shown in Table 3. In the 75 patients who underwent porto-
systemic shunts, only 3 patients died in the ﬁrst year because
of liver function failure with mortality rate of 4% at one year.
Table 2 Porto-systemic shunt patency.
Entire cohort (75) Uncovered shunt (59) Covered shunt (16)
Primary patency 56/75 74.6% 41/59 69.4 % 15/16 93.7%
Reintervention rate 40% 62.5% 14.2%
Assisted-primary patency 71/75 93.3% 55/61 90.1% 16/16 100%
Table 3 Clinical and biochemical data of the patients before
and 2 months after interventions.
Baseline After 60 days
Ascites, no. 98/103 8/103
Dilated abdominal veins 9/103 1/103
Haematemesis, no. 6/103 1/15
ALT1, IU/L 332 (17–619) 31 (18–64)
AST1, IU/L 368 (198–734) 39 (26–64)
GGT1, IU/L 164 (77–297) 123 (55–254)
Albumin, g/dl 3.3 (22–39) 3.5 (33–38)
Bilirubin, mg/dl 2.7 (1.9–3.9) 2.1 (1.7–2.7)
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Budd–Chiari syndrome is an uncommon fatal disorder of the
liver. Recently it was classiﬁed into 4 pathological types. Types
(1) and (2) involve short occlusion at supra hepatic cava (type 1)
or hepatic veins (type 2). For types 3 and 4, there is total occlu-
sion of the hepatic vein without (type 3) or with cava (4). For
type (1) and type (2), there is recanalization in the best treatment
option to restore the normal venous circulation of the liver.
However, for types 3 and 4 a shunt between portal vein and cava
(porto-systemic shunt) is the only option to alleviate liver
congestion and prevent the ongoing liver failure (7,8).
The aim of our study was to evaluate the different radiolog-
ical techniques treating Budd–Chiari patients regarding the
technical and clinical outcomes.
Regarding caval occlusion (type 1), we have treated 9
patients, using caval angioplasty. In 4 cases, occlusion was
total and needed web penetration by RUPS-100 needle. Such
technique was difﬁcult as in the last years and many authors
(9,10) have used different tools (11) as the stiff end of the guide
wires. Results were somehow not satisfactory and the compli-
cation rates were high (8%). We have used another technique
that was safe and effective to re-open the totally occluding
web. Such technique depends on the anatomical features of
the cava. In anterior view of the cavogram, the cava looks to
evacuate contrast direct view and the cava looks to have
postero-anterior direction. Based on such course, we used
the curved Brockenbrough needle to pass through the totally
occlusive membrane. However, to be more accurate, a pigtail
catheter was put in the IVC toughing the occlusion point.
When the antero-posterior and lateral views conﬁrm the align-
ment of both needle and catheter, the needle is pushed to pen-
etrate the web. This technique proved to be effective in
recanalization of cava. This conﬁrmed the results of other
reports (12) that described this technique.
Recanalization of one of the hepatic veins is more difﬁcult
than that of the cava. Percutaneous transhepatic approach was
used before to complete the procedure (12,13). However, tran-shepatic approach has more evident complication, mostly
bleeding (14). We used transjugular approach in most of our
patients (8 patients) or combined with transhepatic approach
in 6 patients. Regarding the transjugular approach, we used
the Brockenbrough needle that has a curve of 30. However
because the angle between the cava and hepatic vein ranges
from 30 to 90, the curve of the needle is increased to adopt.
We used the transhepatic approach only in cases of failure, to
have a guide wire land-marking the vein ostium.
Regarding the technical outcome, our results conformed to
others (15) who reported technical success rate of 100%. In
general, our 26 patients were subjected to recanalization by
dilatation as a primary treatment. Recurrence of stenosis was
high and reached and such patients were subjected to shunting.
After shunting, the primary-assisted rate got higher than the
primary dilatation.
We found that re-stenosis rate of the hepatic vein dilatation
is higher than that of caval lesions which may be related to the
narrowness of the hepatic vein vessel and the fact that the
blood stream returns through the IVC angulately. The cause
of re-stenosis after PTA and shunt implantation is uncertain,
but the following factors may play a role: (1) injury to blood
vessels causes proliferation, migration and excretion of smooth
muscle cell matrix and causes proliferation of the intima, (2)
injury to endothelial cells and laceration of intima causes local
blood vessel thrombosis and organization, and (3) rebound of
blood vessel causes re-stenosis (16). Long-term anticoagulation
post-operation is an effective method of preventing re-stenosis.
The patients that took aspirin and agacore orally after treat-
ment procedures had better outcomes. Other methods for the
prevention of re-stenosis include covered, biodegradable and
electrolytic shunts.
Regarding types 3 and 4 Budd–Chiari disease, the totally
occluded hepatic vein makes recanalization impossible:
whether because of the widespread thrombosis or diffuse
inﬂammatory station. So, such patients should be treated by
portosystemic shunting (17). However, the absence or the
thrombosis of the right hepatic vein makes shunt insertion very
difﬁcult. In such cases we could reach the right portal vein
either by transjugular approach alone or by combined trans-
hepatic transjugular approaches (DIPS). We found that the
TIPS is more effective than DIPS regarding the patency rates.
Regarding our patients, porto-systemic shunt could be tried
in 77 patients, with technical success of 97%. Regarding the
covered shunts, we used Viatorr shunts that are covered by
expanded polytetraﬂuoroethylene membrane.
Some authors reported that tips for cases of terminal
Budd–Chiari could prolong life for liver transplantation. It
also improves their clinical station for longer list for liver
transplantation. We also conﬁrm these reports, where the
overall survival for one year was 86% and the clinical and
biochemical ﬁndings were improved. For our subgroup of
porto-systemic shunt who were subjected to combined tran-
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high. On the other hand group for conventional TIPS showed
better patency rates. This could be attributed to the shape and
pattern of shunt position. In combined approaches, the curve
of shunt is higher and showed higher rate of thrombosis, com-
pared to the relatively straight course of shunt in conventional
TIPS.
Porto-systemic shunt failure or inefﬁcacy of its periodic
revisions does not preclude the performance of a subsequent
surgical operation (18).
The disadvantages of portosystemic shunts are essentially
shunt malfunctions caused by stenosis and/or occlusion of
the intrahepatic tract due to intimal hyperplasia or thrombosis
that generally caused by biliary contamination. In addition,
BCS is characterized by thrombophilia and hypercoagulabil-
ity, which, if not effectively corrected by anticoagulation ther-
apy, increase the incidence of shunt thrombosis up to 80%
after 1 year, with resulting reappearance or worsening of the
complications of portal hypertension (19,20). In recent years,
new shunts covered with polytetraﬂuoroethylene (PTFE)
membranes have become available that dramatically reduce
the rate of shunt malfunction/thrombosis and consequently
the need for periodic revisions, which were very frequent when
only bare shunts were used (21). A recent study compared
TIPS with uncovered and covered shunts in 13 patients with
BCS, reporting primary patency rates of 16.7% vs 100%,
respectively, at 6 months and 0% vs 85.7% at 12 months (22).
Similarly, in our study the subgroup of patients with cov-
ered shunts had signiﬁcantly higher primary patency rates than
those with uncovered shunts (93.7% vs 69.4%) and very low
rates for shunt revision (14.2%).
Shunting the blood decreases portal pressure and could
alleviate gastro-intestinal bleeding and ascites. Moreover, the
liver deconqestiion improves the liver functions and prevents
deterioration. In most cases, TIPS was very effective in con-
trolling the clinical symptoms and signiﬁcantly reducing the
portosystemic pressure gradient and consequently the compli-
cations of portal hypertension (63.3% reduction in the por-
tosystemic pressure gradient) (23,24).
In conclusion, our study conﬁrms previous reports on the
feasibility and efﬁcacy of different interventional techniques
in controlling the complications of portal hypertension and
in improving liver function and consequently the clinical status
of patients with BCS. These techniques proved to be safe and
effective.
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